Jazz Pharmaceuticals (JAZZ) Director Norbert G. Riedel Receives Award

What Happened
Norbert G. Riedel, a director of Jazz Pharmaceuticals plc (JAZZ), received a grant of 1,605 restricted stock units (RSUs) on August 5, 2026. The grant is reported at $0.00 per unit (total reported value $0) and is coded as an award/grant (A). Per the filing, each RSU represents a contingent right to one ordinary share upon vesting; these units will vest in full on July 23, 2027, subject to the reporting person’s continuous service and other conditions.

Key Details

• Transaction date: 2026-08-05 (Form 4 filed 2026-08-07). Filing appears timely (within the two-business-day window for Form 4s).
• Instrument and amount: 1,605 restricted stock units (RSUs); reported price $0.00; total reported value $0.
• Vesting: Units vest in full on July 23, 2027, subject to service and conditions (granted under the Issuer’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan).
• Beneficial ownership: Footnote indicates shares are beneficially owned by the "NORBERT G. RIEDEL 2023 TRUST," an entity owned/controlled by the reporting person and immediate family; the filing does not list total shares owned after this grant.
• Transaction code: A = Award/Grant.

Context
RSUs are a form of compensation that convert to actual shares only upon vesting; no shares changed hands in the open market at grant. Director RSU grants are common as routine compensation and do not, by themselves, indicate a personal buy/sell sentiment.